Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.42 |
| ▸ | FAP | Q12884 | 6/20 | 0.42 |
| ▸ | PREP | P48147 | 6/20 | 0.42 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 3/20 | 0.38 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073490 | 0.87 | DPP4 (0.45) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL9965794 | 0.84 | DPP4 (0.49) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL18474879 | 0.84 | DPP4 (0.68) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL10080104 | 0.83 | DPP4 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL2768336 | 0.83 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30052033 | 0.83 | ACE (0.51) | DPP4DPP8DPP9XIAP | |
| Bromide SCHEMBL1509660 | 0.82 | DPP4 (0.49) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL13380009 | 0.81 | XIAP (0.47) | DPP4DPP8DPP9XIAPMLX | |
| SCHEMBL10140841 | 0.81 | CYP3A4 (0.51) | DPP4DPP8DPP9PREP | |
| SCHEMBL3269007 | 0.81 | CYP3A4 (0.51) | DPP4DPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | DPP4 2991/4885DPP8 2608/4885DPP9 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.